LEDERLE-PRAXIS' HIBTITER APPROVED FOR INFANTS DOWN TO TWO

LEDERLE-PRAXIS' HIBTITER APPROVED FOR INFANTS DOWN TO TWO MONTHS of age by FDA on Oct. 4. The approval of Lederle-Praxis' conjugate Haemophilus B vaccine for use in a primary immunization series in infants at ages two, four, and six months comes just six weeks after FDA's Vaccine and Related Biological Products Advisory Committee agreed that the vaccine is safe and effective for infants under 15 months of age. The approved regimen also calls for the administration of booster shots at 15 months or more. The approval gives Lederle a victory in the three-way race in the U.S. to become the first producer of a Haemophilus B conjugate vaccine approved for use in small infants. Lederle edged out Merck's PedvaxHIB conjugate vaccine, which was also reviewed at the Aug. 20 advisory committee meeting and, like Lederle's vaccine, was considered by the committee to be safe and effective in infants ("The Pink Sheet" Aug. 27, p.8). However, the advisory committee had some questions about the duration of antibody response to the Merck vaccine. Merck told the advisory committee that the company is in the process of doing a follow-up sampling of antibodies in about half of the subjects who participated in the clinical trial that served as the basis for the PLA. Connaught's ProHIBIT was the first conjugate Haemophilus influenza vaccine to reach the U.S. market, following its approval in December 1987 for use in children 18-60 months old. However, Connaught's effort to expand the availability of its vaccine to small infants received a setback in January when the Vaccine and Related Biologicals Advisory Committee was unable to reach a consensus on whether the firm's data supported use of the vaccine in infants down to four months of age ("The Pink Sheet" Jan. 29, T&G-8). At issue were poor efficacy results from a study conducted in Alaska with the Connaught vaccine. Lederle's PLA for HibTITER was based on administration of the vaccine to 60,000 infants at the Kaiser Permanente Pediatric Vaccine Study Center in Oakland, California. A Kaiser Permanente investigator reported to the advisory committee that 97% of infants had 1 mcg or greater of antibody after the three innoculation series and that 71% of infants sustained that level of antibody a year after the series. After the booster shot, antibody levels above 1 mcg were found in 97% of the infants. An Oct. 4 HHS press release on the expanded use of HibTITER noted that "the vaccine provided high levels of protection until the recommended Booster dose." The Kaiser Permanente Trials also demonstrated that HibTITER can be administered simultaneously with other traditional infant immunizations. FDA reported that side effects resulting from simultaneous immunization with MMR, Oral Polio and DPT vaccine were only "mild and transient, including swelling and warmth at the vaccination site and occasional fever." The HHS press release, quoting Secretary Sullivan, predicts that "the new use of this vaccine will prevent a serious, contagious disease responsible for the majority of cases of meningitis." HHS also noted that HibTITER is "the first approval of a vaccine for routine use in infants in almost 30 years." To promote HibTITER's new indication, Lederle-Praxis is organizing a major educational/publicity campaign. In the next week, the company expects to begin mailing "Dear Doctor" letters to more than 100,000 pediatricians. Lederle also plans to distribute free brochures to parents through physician offices, daycare centers and nursery schools, and has established an "800" number to provide additional information to parents interested in the vaccine.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

US FDA’s Familiar Drug Pricing To-Do List

 

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric

 

FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.